SB 664, titled the NIH Reform Act, would reorganize the National Institute of Allergy and Infectious Diseases (NIAID) by replacing it with three separate institutes within the National Institutes of Health: the National Institute of Allergic Diseases, the National Institute of Infectious Diseases, and the National Institute of Immunologic Diseases. The bill amends the Public Health Service Act to create each institute, define its general research and programmatic purpose, and assign each a director appointed by the President with Senate confirmation for five-year terms, renewable once.
The legislation also transfers and renumbers existing statutory authorities tied to NIAID so that responsibilities related to allergic diseases, infectious diseases, and immunologic diseases are split among the new entities. It provides for an orderly transition of authority from the current NIAID structure to the new institutes and states that references in law, regulations, guidance, and other federal documents to NIAID will be treated as references to the appropriate successor institute. In effect, the bill would substantially rewrite the statutory framework governing this part of NIH while preserving the underlying research functions.
The bill’s impact would be primarily on federal public health law and NIH administration rather than on private parties directly. It would amend multiple sections of the Public Health Service Act, terminate the current NIAID director position upon enactment, and create new leadership and organizational lines for research on allergies, infectious diseases, tropical diseases, and immunologic disorders. Agencies, researchers, and grant recipients that interact with NIAID would need to adjust to the new institutional structure and terminology.
Because there are no committee transcripts or recorded votes in the provided context, there is no documented debate or vote history to gauge broader sentiment. Based on the bill text alone, the measure appears to reflect a reform-oriented view that NIH’s current structure should be divided into more specialized institutes. The absence of recorded opposition or support in the supplied materials means sentiment cannot be assessed beyond noting that the bill was introduced and referred to committee.
The main point of contention likely concerns whether splitting NIAID into three institutes would improve scientific focus and accountability or instead create administrative duplication, transition challenges, and fragmentation of related research areas. The bill’s supporters, Senators Paul and Tuberville, appear to favor restructuring, while any opposition would likely come from those concerned about disrupting existing NIH operations, complicating coordination among closely related disease areas, or altering the current balance of authority within NIH.
SB 664 would amend the Public Health Service Act to dismantle the current NIAID statutory framework and replace it with three new NIH institutes, each with its own director, purpose, and transferred authorities. It would also require conforming changes across federal law and deem existing references to NIAID to refer to the appropriate successor institute, affecting NIH governance, research administration, and related federal documents and regulations.
No votes or committee discussion were provided, so there is no recorded legislative sentiment to summarize. The bill was introduced and referred to the Senate HELP Committee, suggesting it is at an early stage. The text indicates a reform-minded effort to reorganize NIH, but the supplied materials do not show whether that approach has support or opposition among lawmakers.
The likely controversy is structural: whether NIAID should be split into separate institutes for allergic diseases, infectious diseases, and immunologic diseases. Supporters would argue the split creates clearer focus and specialized leadership, while critics would likely worry about duplication, administrative burden, transition costs, and the loss of coordination across overlapping research areas. No specific objections or endorsements are recorded in the provided context.